Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · February 06, 2024

Patient-Reported Outcomes in Cisplatin-Ineligible Patients With Advanced Urothelial Cancer After First-Line Enfortumab Vedotin ± Pembrolizumab

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab
J. Clin. Oncol 2024 Jan 12;[EPub Ahead of Print], MI Milowsky, PH O'Donnell, CJ Hoimes, DP Petrylak, TW Flaig, HH Moon, TW Friedlander, N Mar, RR McKay, S Srinivas, G Gravis, C Ramamurthy, M Bupathi, S Bracarda, P Wright, Z Hepp, AS Carret, Y Yu, R Dillon, R Kataria, JL Beaumont, I Purnajo, JE Rosenberg

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading